CDK2 inhibitor BLU-222 synergizes with CDK4/6 inhibitors in drug resistant breast cancers through p21/p27 induction

Journal:

Nature Communications

Published:

2026-01-22

DOI:

10.1038/s41467-025-67865-4

Affiliations:

7

Authors:

21

Go to article

Institutions	Authors	Share
The University of Texas MD Anderson Cancer Center, United States of America (USA)	18.500000 18.500000	0.88
Baylor College of Medicine (BCM), United States of America (USA)	1.000000	0.05
Blueprint Medicines, United States of America (USA)	1.000000	0.05
Sun Yat-sen Memorial Hospital, SYSU, China	0.500000	0.02

Interested in Oncology and Carcinogenesis?